| Project | Indication | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Regulatory Approval |
|---|---|---|---|---|---|---|
| Motixafortide (BL-8040) | Stem Cell Mobilization | |||||
| Pancreatic cancer | ||||||
| AML | ||||||
| AGI-134 | Solid tumors |
Motixafortide (BL-8040)
Motixafortide targets CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human ...
INDICATIONS : 3
CLINICAL STUDIES : 12
AGI-134
AGI-134 is a synthetic alpha-Gal glycolipid in development for solid tumors that is highly differentiated from other cancer ...
